Long-term efficacy, safety and tolerability of Remoxy for the management of chronic pain

References

• Institute of medicine report from the committee on advancing pain research. Relieving pain in America, a blueprint for transforming prevention, care, education and research. The national academies press; Washington, D.C: 2011
   Google Scholar
• The American Academy of Pain Medicine. AAPM facts and figures on pain. AAPM Facts and Figures on Pain 2013(11 April 2013
   Google Scholar
• American Pain Foundation. Voices of chronic pain: a national study conducted for American pain foundation; (2006).
   Google Scholar
• Gaskin DJ, Richard P. The economic costs of pain in the United States. J Pain 2012;13(8):715-24
   PubMed Web of Science ®Google Scholar
• Stewart WF, Ricci JA, Chee E, Morganstein D. Lost productive work time costs from health conditions in the United States: results from the American Productivity Audit. J Occup Environ Med 2003;45(12):1234-46
   PubMed Web of Science ®Google Scholar
• Lalovic B, Kharasch E, Hoffer C, et al. Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites. Clin Pharmacol Ther 2006;79(5):461-79
   PubMed Web of Science ®Google Scholar
• Gasche Y, Daali Y, Fathi M, et al. Codeine intoxication associated with ultrarapid CYP2D6 metabolism. N Engl J Med 2004;351(27):2827-31
   PubMed Web of Science ®Google Scholar
• Otton SV, Wu D, Joffe RT, et al. Inhibition by fluoxetine of cytochrome P450 2D6 activity. Clin Pharmacol Ther 1993;53(4):401-9
   PubMed Web of Science ®Google Scholar
• Virk MS, Williams JT. Agonist-specific regulation of mu-opioid receptor desensitization and recovery from desensitization. Mol Pharmacol 2008;73(4):1301-8
   PubMed Web of Science ®Google Scholar
• Nielsen CK, Ross FB, Lotfipour S, et al. Oxycodone and morphine have distinctly different pharmacological profiles: radioligand binding and behavioural studies in two rat models of neuropathic pain. Pain 2007;132(3):289-300
   PubMed Web of Science ®Google Scholar
• Kalso E. How different is oxycodone from morphine? Pain 2007;132(3):227-8
   PubMed Web of Science ®Google Scholar
• Nozaki C, Saitoh A, Kamei J. Characterization of the antinociceptive effects of oxycodone in diabetic mice. Eur J Pharmacol 2006;535(1-3):145-51
   Google Scholar
• Nozaki C, Kamei J. Involvement of mu1-opioid receptor on oxycodone-induced antinociception in diabetic mice. Eur J Pharmacol 2007;560(2-3):160-2
   Google Scholar
• Cicero TJ, Inciardi JA, Munoz A. Trends in abuse of Oxycontin and other opioid analgesics in the United States: 2002-2004. J Pain 2005;6(10):662-72
   PubMed Web of Science ®Google Scholar
• Mccormick CG, Henningfield JE, Haddox JD, et al. Case histories in pharmaceutical risk management. Drug Alcohol Depend 2009;105(Suppl 1):S42-55
   PubMed Web of Science ®Google Scholar
• Wu LT, Pilowsky DJ, Patkar AA. Non-prescribed use of pain relievers among adolescents in the United States. Drug Alcohol Depend 2008;94(1-3):1-11
   PubMed Web of Science ®Google Scholar
• Manchikanti L, Fellows B, Ailinani H, Pampati V. Therapeutic use, abuse, and nonmedical use of opioids: a ten-year perspective. Pain Physician 2010;13(5):401-35
   PubMed Web of Science ®Google Scholar
• Manchikanti L, Helm S2nd, Fellows B, et al. Opioid epidemic in the United States. Pain Physician 2012;15(3 Suppl):ES9-38
   PubMed Web of Science ®Google Scholar
• Hall AJ, Logan JE, Toblin RL, et al. Patterns of abuse among unintentional pharmaceutical overdose fatalities. JAMA 2008;300(22):2613-20
   PubMed Web of Science ®Google Scholar
• Manchikanti L, Singh A. Therapeutic opioids: a ten-year perspective on the complexities and complications of the escalating use, abuse, and nonmedical use of opioids. Pain Physician 2008;11(2 Suppl):S63-88
   PubMed Web of Science ®Google Scholar
• Substance Abuse and Mental Health Services Administration. Results from the 2012 National survey on drug use and health: summary of national findings, NSDUH Series H-46, HHS Publication No. (SMA) 13-4795. Results from the 2012 National Survey on Drug Use and Health: Summary of National Findings, NSDUH Series H-46, HHS Publication No. (SMA) 2013; 13-4795
   Google Scholar
• Birnbaum HG, White AG, Schiller M, et al. Societal costs of prescription opioid abuse, dependence, and misuse in the United States. Pain Med 2011;12(4):657-67
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Vital Signs: overdoses of prescription opioid pain relievers – United States, 1999–2008. MMWR 2011;60:1-6
   Google Scholar
• Moorman-Li R, Motycka CA, Inge LD, et al. A review of abuse-deterrent opioids for chronic nonmalignant pain. P T 2012;37(7):412-18
   PubMedGoogle Scholar
• Butler SF, Cassidy TA, Chilcoat H, et al. Abuse rates and routes of administration of reformulated extended-release oxycodone: initial findings from a sentinel surveillance sample of individuals assessed for substance abuse treatment. J Pain 2013;14(4):351-8
   PubMed Web of Science ®Google Scholar
• Friedmann N, Klutzaritz V, Webster L. Long-term safety of Remoxy® (extended-release oxycodone) in patients with moderate to severe chronic osteoarthritis or low back pain. Pain Med 2011;12(5):755-60
   PubMed Web of Science ®Google Scholar
• Roland CL, Setnik B, Cleveland JM, Brown DA. Clinical outcomes during opioid titration following initiation with or conversion to Remoxy®, an extended-release formulation of oxycodone. Postgrad Med 2011;123(4):148-59
   PubMed Web of Science ®Google Scholar
• Friedmann N, Klutzaritz V, Webster L. Efficacy and safety of an extended-release oxycodone (Remoxy) formulation in patients with moderate to severe osteoarthritic pain. J Opioid Manag 2011;7(3):193-202
   PubMedGoogle Scholar
• Setnik B, Roland CL, Cleveland JM, Webster L. The abuse potential of Remoxy(®), an extended-release formulation of oxycodone, compared with immediate- and extended-release oxycodone. Pain Med 2011;12(4):618-31
   PubMed Web of Science ®Google Scholar
• Mccoll S, Sellers EM. Research design strategies to evaluate the impact of formulations on abuse liability. Drug Alcohol Depend 2006;83(Suppl 1):S52-62
   PubMedGoogle Scholar
• Osgood ED, Eaton TA, Trudeau JJ, Katz NP. A brief survey to characterize oxycodone abuse patterns in adolescents enrolled in two substance abuse recovery high schools. Am J Drug Alcohol Abuse 2012;38(2):166-70
   PubMed Web of Science ®Google Scholar
• Butler SF, Black RA, Cassidy TA, et al. Abuse risks and routes of administration of different prescription opioid compounds and formulations. Harm Reduct J 2011;8:29
   PubMed Web of Science ®Google Scholar
• US department of health and human services, food and drug administration, center for drug evaluation and research. Guidance for Industry. Abuse-Deterrent Opioids-Evaluaiton and Labeling (Draft). (2013).
   Google Scholar
• Butler SF, Black R, Grimes Serrano JM, et al. Estimating attractiveness for abuse of a not-yet-marketed ‘abuse-deterrent’ prescription opioid formulation. Pain Med 2010;11(1):81-91
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (Cdc). Vital signs: overdoses of prescription opioid pain relievers–United States, 1999–2008. Morb Mortal Wkly Rep 2011;60(43):1487-92
   PubMedGoogle Scholar
• Chou R, Fanciullo GJ, Fine PG, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 2009;10(2):113-30
   PubMed Web of Science ®Google Scholar
• Gourlay DL, Heit HA, Almahrezi A. Universal precautions in pain medicine: a rational approach to the treatment of chronic pain. Pain Med 2005;6(2):107-12
   PubMed Web of Science ®Google Scholar
• Policy OONDC. Prescription Drug Abuse. Prescription Drug Abuse 2014( July 11)( 2004).
   Google Scholar